Study result
Logotype for Invivyd Inc

Invivyd (IVVD) Study result summary

Event summary combining transcript, slides, and related documents.

Logotype for Invivyd Inc

Study result summary

3 Nov, 2026

Study design

  • Phase 3 LIBERTY randomized 210 healthy adults aged 18–49 in a double-blind, active-controlled study of VYD2311, an mRNA vaccine, or both; safety assessments covered 6 and 56 days.

  • LIBERTY evaluated safety, tolerability, and immunologic interference; it had no placebo arm and was not designed to establish efficacy.

Safety and tolerability

  • VYD2311 met LIBERTY’s primary and secondary endpoints, showing superior safety and tolerability to the mRNA vaccine.

  • At 6 days, any TEAE, injection-site reaction, or hypersensitivity occurred in 56.5% of VYD2311 recipients versus 91.4% with vaccine (P<0.0001); systemic adverse events occurred in 44.1% versus 68.1% (P=0.008).

  • At 56 days, any TEAE, injection-site reaction, or hypersensitivity occurred in 60.9% of VYD2311 recipients versus 83.1% with vaccine (P<0.0001).

  • No VYD2311-related adverse events exceeded Grade 2, and no hypersensitivity, anaphylaxis, myocarditis, or pericarditis occurred in any arm.

  • Combination dosing was associated with fewer systemic events than vaccine alone, suggesting improved vaccine tolerability.

Immunogenicity

  • Co-administration increased total neutralizing titers by ~2.5x versus vaccine alone, with no evidence of immunologic interference.

  • After VYD2311 was selectively removed from samples, vaccine-induced neutralization titers matched those in the vaccine-only arm.

  • Monotherapy immunogenicity findings were preliminary and underpowered; further review alongside DECLARATION data was anticipated.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Invivyd